Syndecan-1

Syndecan-1

Syndecan-1 Informations sur la molécule

Molecule Name
Syndecan-1
Alias de la molécule
SDC1,Syndecan-1,CD138,SYND1,SDC
Drug Development Progress
Nombre de médicaments cliniques2
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 1 Clinical
Alias de la cible
Syndecan Proteoglycan 1,CD138 Antigen,SYND1,SDC,Heparan Sulfate Proteoglycan Fibroblast Growth Factor Receptor,Syndecan,CD138,Syndecan-1,SDC1,Syndecan 1
Contexte de la molécule
Syndecan-1 (SYND1 or SDC1) is also known as CD antigen CD138, is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. The syndecans mediate cell binding, cell signaling, and cytoskeletal organization and syndecan receptors are required for internalization of the HIV-1 tat protein. The syndecan-1 / SDC1 protein functions as an integral membrane protein and participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins. It is a useful marker for plasma cells, but only if the cells tested are already known to be derived from blood.

Syndecan-1 Liste de produits

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
ATLCAR.CD138 (UNC Lineberger Comprehensive Cancer Center)Phase 1 ClinicalUnc Lineberger Comprehensive Cancer Center
Immune System Diseases; Multiple Myeloma
Details
QXL-138AMQXL-138AMPhase 1 ClinicalNammi Therapeutics Inc
Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Gastrointestinal Neoplasms; Lung Neoplasms; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours
Details